Table 1 Characteristics of the included studies
Author (year) | Study design | PCOS criteria | Age (years) (T/C) | Regimen | Total sample sizes | Duration (weeks) | |
|---|---|---|---|---|---|---|---|
Experimental group | Control group | ||||||
Comparison between exenatide versus metformin | |||||||
 Elkind-Hirsch. K et al.,2008 [31] | Randomized, clinical, prospective, outpatient trial | Rotterdam 2003 criteria | (28.2 ± 1.1)/(27.7 ± 1.3) | Exenatide 10ug bid | Metformin 1000 mg bid | 40 | 24Weeks |
 Li. R.Y et al., 2020 [17] | Randomized, clinical, prospective trial | NA | NA | Exenatide | Metformin | 147 | 12Weeks |
 Li. R et al.,2022 [16] | Randomized, clinical, prospective trial | Rotterdam criteria | (28.22 ± 3.89)/(27.78 ± 3.81) | Exenatide 5 μg bid | Metformin 1000 mg bid | 160 | 12Weeks |
 Liu. X et al.,2017 [18] | Randomized, clinical, prospective trial | Rotterdam criteria | (27.93 ± 2.7)/(27.69 ± 3.80) | Exenatide 10 μg bid | Metformin 1000 mg bid | 176 | 12Weeks |
 Tao. T et al.,2021 [32] | Randomized, clinical, parallel-group controlled trial | Rotterdam 2003 criteria | NA | Exenatide 10 μg bid | Metformin 1000 mg tid | 100 | 12Weeks |
 Wang. J et al., 2017 [33] | Randomized, clinical, single-center, controlled, single-blind trial | Rotterdam criteria | (25.92 ± 6.75)/(25.67 ± 7.33) | Exenatide 10 μg bid | Metformin 500 mg bid | 78 | 12Weeks |
 Zheng. S et al.,2017 [10] | Randomized, clinical, prospective trial | Rotterdam 2003 criteria | (27.20 ± 3.1)/(27.7 ± 2.7) | Exenatide 10 μg bid | Metformin 1000 mg bid | 176 | 12Weeks |
 Zheng. S et al.,2019 [20] | Randomized, clinical, prospective trial | Rotterdam criteria | (27.2 ± 1.76)/(27.7 ± 1.64) | Exenatide 10 μg bid | Metformin 1000 mg bid | 82 | 12Weeks |
Comparison between exenatide + metformin and metformin alone | |||||||
 Elkind-Hirsch. K et al.,2008 [31] | Randomized, clinical, prospective, outpatient trial | Rotterdam 2003 criteria | (32.1 ± 0.7)/(27.7 ± 1.3) | Exenatide 10 μg bid + Metformin 1000 mg bid | Metformin 1000 mg Bid | 40 | 24eeks |
 Ma. R. L et al.,2021 [21] | Randomized, clinical, prospective, outpatient trial | Rotterdam criteria | (30.10 ± 4.52)/(28.17 ± 4.40) | exenatide 2 mg qw + Metformin 500 mg tid | Metformin 500 mg tid | 50 | 12Weeks |
 Tao. T et al.,2021 [32] | Randomized, clinical, parallel-group controlled trial | Rotterdam 2003 criteria | NA | Exenatide 10 μg bid + Metformin 1000 mg tid | Metformin 1000 mg tid | 100 | 12Weeks |